Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic
management options or who require long-term administration of corticosteroids to control
their disease are particularly challenging to manage. The pathogenesis of pericarditis
involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution)
is known to have anti-inflammatory properties, including modulation of inflammasome
signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the
resolution of pericarditis symptoms, assess improvement in objective measures of disease, and
during the extension period, assess the feasibility of weaning concomitant background therapy
including corticosteroids while taking CardiolRxTM.